Paclitaxel-Bleomycin/Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker Decline: Randomized Phase II Trial | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Paclitaxel-Bleomycin/Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker Decline: Randomized Phase II Trial	Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, gonadal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, testicular cancer, testicular disorder	Recruiting	Phase 2	2026-09-29		NCT07847190

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Blokhin's Russian Cancer Research Center	17
Moscow Multidisciplinary Clinical Center "Kommunarka"	7
N.N. Petrov National Medical Research Center of Oncology	11
National Medical Research Radiological Centre of the Ministry of Health of Russia	9

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
N.N. Blokhin National Medical Research Center of Oncology	Moscow	Russia	1